Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$0.59
-7.7%
$0.69
$0.51
▼
$1.69
$26.89M1.65157,325 shs160,175 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-7.66%-5.00%-7.96%-16.77%-58.09%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$0.59
-7.7%
$0.69
$0.51
▼
$1.69
$26.89M1.65157,325 shs160,175 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-7.66%-5.00%-7.96%-16.77%-58.09%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
2.33
Hold$3.50492.22% Upside

Current Analyst Ratings Breakdown

Latest BONH, LVCG, MIRA, and CCPA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/2/2026
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
UpgradeSell (E+) ➝ Sell (D-)
9/17/2026
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
Initiated CoverageBuy$3.50
8/20/2026
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/A$0.25 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$10.44M-$1.24N/AN/AN/AN/A-106.95%-104.18%12/2/2026 (Estimated)

Latest BONH, LVCG, MIRA, and CCPA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
12/2/2026N/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.03N/AN/AN/AN/AN/A
11/16/2026Q3 2026
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.03-$0.03N/A-$0.03N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/A
200.08
200.08

Institutional Ownership

CompanyInstitutional Ownership
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
35.16%

Insider Ownership

CompanyInsider Ownership
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
19.89%
CompanyEmployeesShares OutstandingFree FloatOptionable
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
242.02 million33.66 millionNot Optionable

Recent News About These Companies

MIRA-55 shows 500-fold opioid receptor separation in new findings
MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Up 0.3% - Time to Buy?
MIRA advances Ketamir-2 Phase 2a neuropathy program
MIRA Pharmaceuticals stock logo

MIRA Pharmaceuticals NASDAQ:MIRA

$0.59 -0.05 (-7.66%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$0.60 +0.01 (+1.18%)
As of 11/18/2026 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.